The efficency was assessed of the screening for extrahepatic biliary atresia by measuring total bile acids absorbed in dried blood spots at around 5 days of age. When the cut‐off level was 54.0 μmol/l, the sensitivity, the specificty and the efficiency of the screening test were 87.9%, 93.9% and 93.9% respectively. The case‐finding rate was 0.009% in this type of screening which was three times as many as an early case‐finding rate by population screening. These results suggest that teh efficiency of this screening is acceptable.
We have developed a quantitative system to measure serum concentrations of the soluble form of human IGF-II receptor (IGF-IIR). The soluble form retains the ability to bind to IGF-II and proteins with M6P moieties in circulating blood. IGF-IIR does not only control the degradation of IGF-II, but also inhibits DNA synthesis by modifying the IGF-II action. The measurement of serum concentrations of the soluble form is able to clarify the growth mechanism in vivo. The system employs an enzyme immunoassay (EIA) making use of antibodies to peptides 1103~1119 amino acid (AA) of IGF-IIR. We could obtain two single bands at about 220 kDa corresponding to the soluble form and at about 290 kDa corresponding to the cell membrane-associated form by Western blotting. According a recent report, the soluble form was 220 kDa, and the measured level was 700 ± 230 ng/ml in healthy adults. In our trial data, the measured mean level was about 724 ± 134 ng/ml in five healthy adults. These data were nearly coincident. Consequently this antibody has high specificity for the soluble form in blood and the cell membrane associated form of IGF-IIR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.